Year: 2019
Type: article
Abstract: New non-invasive approaches that can complement and improve on current strategies for colorectal cancer (CRC) screening and management are urgently needed. A growing number of publications have documented that components of tumors, which are shed into the circulation, can be detected in the form of liquid biopsies and can be used to detect CRC at early stages, to predict response to certain therapies and to detect CRC recurrence in a minimally invasive way. The analysis of circulating tumor DNA (ctDNA), tumor-derived cells (CTC, circulating tumor cells) or circulating microRNA (miRNA) in blood and other body fluids, have a great potential to improve different aspects of CRC management. The challenge now is to find which types of components, biofluids and detection methods would be the most suitable to be applied in the different steps of CRC detection and treatment. This chapter will provide an up to date review on ctDNA, CTCs and circulating miRNAs as new biomarkers for CRC, either for clinical management or early detection, highlighting their advantages and limitations.
Source: Molecular Aspects of Medicine
Institutions: Hospital Clínic de Barcelona, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Consorci Institut D'Investigacions Biomediques August Pi I Sunyer, Universitat de Barcelona, Charles University, Czech Academy of Sciences, Institute of Experimental Medicine, Düsseldorf University Hospital, Heinrich Heine University Düsseldorf, Oslo University Hospital, Karolinska University Hospital, Karolinska Institutet, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos, Centro de Investigación Biomédica en Red de Cáncer, The Netherlands Cancer Institute, Medical University of Graz
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: hybrid
Estimated APC paid: $3,150
Funders: Centres de Recerca de Catalunya, European Commission, European Cooperation in Science and Technology, Fundación Científica Asociación Española Contra el Cáncer, Generalitat de Catalunya, Ministerstvo Zdravotnictví Ceské Republiky, Ministerio de Economía y Competitividad, Stockholms Läns Landsting, KWF Kankerbestrijding, Christian Doppler Forschungsgesellschaft, Centro de Investigación Biomédica en Red de Cáncer, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Instituto de Salud Carlos III
Awards: G1627349266, G2262670400, G3350523561, Evaluación de la capacidad pronóstica y del papel funcional de microRNA candidatos en el adenocarcinoma ductal pancreático, G4039782410, G5064570577, G5312756924, G5801982654, G629507414, G6345388124, G6692840757, G6903488607, G7152041638, G7412172793, G8194728800
OpenAlex ID: W2950512766